Molecular Weight

204.27 g/mol

Molecular Formula

C₁₂H₁₆N₂O

XLogP3

2.1

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Rotatable Bond Count

Exact Mass

204.126263138 g/mol

Monoisotopic Mass

204.126263138 g/mol

Topological Polar Surface Area

39.3 Å²

Heavy Atom Count

Formal Charge

Complexity

208

Isotope Atom Count

Defined Atom Stereocenter Count

Undefined Atom Stereocenter Count

Defined Bond Stereocenter Count

Undefined Bond Stereocenter Count

Covalently Bonded Unit Count

Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)

Psilo Scientific Ltd

Canada

Medlab Asia & Asia Health

Not Confirmed

Psilo Scientific Ltd

Canada

Medlab Asia & Asia Health

Not Confirmed

Psilo Scientific Ltd

Canada

Medlab Asia & Asia Health

Not Confirmed

Cayman Pharma s.r.o

Czech Republic

Medlab Asia & Asia Health

Not Confirmed

Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

Contact Supplier

Czech Republic

Virtual Booth

Digital Content

Psilocin

About the Company : Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostagla...

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.